Adolor at work on Entereg NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adolor is "working diligently" to submit an NDA for Entereg (alvimpoan) late in the first half of 2004, for management of postoperative ileus. FDA has designated Entereg as a fast-track product, the company announces Feb. 24...